TRAP Inhibitors
The chemical class of TRAP inhibitors comprises a diverse array of compounds that modulate TRAP activity through direct or indirect mechanisms. These inhibitors impact TRAP, a protein involved in lysosomal function, cellular homeostasis, and proteolysis. Chloroquine, Bafilomycin A1, Leupeptin, E-64, Concanamycin A, Pepstatin A, E64d, NH4Cl, Clomipramine, Ammonium Ionophore I (Monensin), Pepstatin, Latrunculin A, and Ionomycin represent a selection of TRAP inhibitors with distinct modes of action. Chloroquine, a lysosomotropic agent, indirectly inhibits TRAP by disrupting endosomal acidification, impacting cellular trafficking and lysosomal processes. Bafilomycin A1, a V-ATPase inhibitor, indirectly modulates TRAP by preventing lysosomal acidification, disrupting pH-dependent processes. Leupeptin, E-64, and E64d, protease inhibitors, indirectly influence TRAP by disrupting lysosomal proteolysis, altering TRAP-mediated activities. Concanamycin A, another V-ATPase inhibitor, indirectly inhibits TRAP by preventing lysosomal acidification, affecting pH-dependent processes.
Pepstatin A and Pepstatin, aspartic protease inhibitors, indirectly impact TRAP by inhibiting lysosomal proteolysis, leading to altered TRAP function. NH4Cl, an ammonium chloride, indirectly inhibits TRAP by raising lysosomal pH, disrupting pH-dependent processes. Clomipramine, a serotonin reuptake inhibitor, indirectly influences TRAP by modulating serotonin signaling and intracellular pathways. Ammonium Ionophore I (Monensin), an ionophore, indirectly modulates TRAP by disrupting ion gradients, altering cellular homeostasis. Latrunculin A, an actin polymerization inhibitor, indirectly modulates TRAP by disrupting actin filaments, influencing cellular morphology and TRAP-mediated processes. Ionomycin, a calcium ionophore, indirectly inhibits TRAP by disrupting calcium homeostasis, altering intracellular calcium levels. The chemical class of TRAP inhibitors offers valuable tools for researchers studying lysosomal function, cellular proteolysis, and associated physiological processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, a lysosomotropic agent, indirectly inhibits TRAP by interfering with endosomal acidification. By disrupting pH-dependent processes, Chloroquine impacts cellular trafficking, inhibiting TRAP function. The compound acts as an indirect inhibitor by altering the endosomal environment, leading to impaired TRAP-mediated processes. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1, a V-ATPase inhibitor, indirectly modulates TRAP by preventing lysosomal acidification. Through V-ATPase inhibition, Bafilomycin A1 disrupts pH-dependent processes, affecting TRAP function. The compound acts as an indirect inhibitor by altering the lysosomal environment, leading to impaired TRAP-mediated activities. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin, a protease inhibitor, indirectly influences TRAP by inhibiting lysosomal proteolysis. By preventing protease activity, Leupeptin impacts TRAP-mediated processes within lysosomes. The compound acts as an indirect inhibitor by disrupting lysosomal protein degradation, leading to altered TRAP function. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E64d, a cysteine protease inhibitor, indirectly modulates TRAP by inhibiting lysosomal proteolytic enzymes. By targeting cysteine proteases, E64d disrupts lysosomal processes, influencing TRAP function. The compound acts as an indirect inhibitor by interfering with lysosomal protein degradation, leading to impaired TRAP-mediated activities. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A, a V-ATPase inhibitor, indirectly inhibits TRAP by preventing lysosomal acidification. Through V-ATPase inhibition, Concanamycin A disrupts pH-dependent processes, affecting TRAP function. The compound acts as an indirect inhibitor by altering the lysosomal environment, leading to impaired TRAP-mediated activities. | ||||||
Clomipramine hydrochloride | 17321-77-6 | sc-203898 | 1 g | $38.00 | 2 | |
Clomipramine, a serotonin reuptake inhibitor, indirectly influences TRAP by modulating serotonin signaling. By affecting intracellular signaling pathways, Clomipramine impacts TRAP-mediated processes. The compound acts as an indirect inhibitor by influencing serotonin-dependent mechanisms, leading to altered TRAP function. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Ammonium Ionophore I (Monensin), an ionophore, indirectly modulates TRAP by disrupting ion gradients. Through ionophore activity, it interferes with cellular homeostasis, affecting TRAP-mediated processes. The compound acts as an indirect inhibitor by altering ion concentrations, leading to impaired TRAP function. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin A, an actin polymerization inhibitor, indirectly modulates TRAP by influencing cytoskeletal dynamics. By disrupting actin filaments, Latrunculin A impacts cellular morphology and TRAP-mediated processes. The compound acts as an indirect inhibitor by altering the cytoskeletal structure, leading to impaired TRAP function. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin, a calcium ionophore, indirectly inhibits TRAP by disrupting calcium homeostasis. Through ionophore activity, Ionomycin interferes with intracellular calcium levels, affecting TRAP-mediated processes. The compound acts as an indirect inhibitor by altering calcium concentrations, leading to impaired TRAP function. | ||||||